The Role of NK Cells in EBV Infection and EBV-Associated NPC

• Published in: Viruses 2021-02, Vol.13 (2), p.300
• Main Authors: Png, Yi Tian, Yang, Audrey Zhi Yi, Lee, Mei Ying, Chua, Magdalene Jahn May, Lim, Chwee Ming
• Format: Article
• Language: English
• Subjects: Epstein-Barr Virus (EBV); Nasopharyngeal Carcinoma (NPC); NK cells; Review
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v13020300

A vast majority of the population worldwide are asymptomatic carriers of Epstein-Barr Virus (EBV). However, some infected individuals eventually develop EBV-related cancers, including Nasopharyngeal Carcinoma (NPC). NPC is one of the most common EBV-associated epithelial cancers, and is highly prevalent in Southern China and Southeast Asia. While NPC is highly sensitive to radiotherapy and chemotherapy, there is a lack of effective and durable treatment among the 15%-30% of patients who subsequently develop recurrent disease. Natural Killer (NK) cells are natural immune lymphocytes that are innately primed against virus-infected cells and nascent aberrant transformed cells. As EBV is found in both virally infected and cancer cells, it is of interest to examine the NK cells' role in both EBV infection and EBV-associated NPC. Herein, we review the current understanding of how EBV-infected cells are cleared by NK cells, and how EBV can evade NK cell-mediated elimination in the context of type II latency in NPC. Next, we summarize the current literature about NPC and NK cell biology. Finally, we discuss the translational potential of NK cells in NPC. This information will deepen our understanding of host immune interactions with EBV-associated NPC and facilitate development of more effective NK-mediated therapies for NPC treatment.